# North America Clinical Laboratory Test Market

> North America Clinical Laboratory Test Market Research Report Information By Type of Laboratory (Hospital based, Central/Independent, Physician Office Laboratory, and Others), By Type of Test (CBC and Routine Blood Test, Anatomic Pathology, Molecular Test, Immunology Test, Drug Test, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.9%
- **2024:** $ 45 Billion
- **2025:** $ 49 Billion
- **2035:** $ 115 Billion
- **Key Players:** Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), PerkinElmer Inc. (US), bioMérieux SA (FR), Ortho Clinical Diagnostics (US)

**Report ID:** MRFR/LS/1651-CR · **Pages:** 85 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** January 13, 2026

**URL:** https://www.marketresearchfuture.com/reports/america-clinical-laboratory-test-market-2249

---

## Market Summary

## **North America Clinical Laboratory Test Market Overview**

North America Clinical Laboratory Test Market Size was valued at USD 19.54 Billion in 2023. The North America Clinical Laboratory Test market industry is projected to grow from USD 20.98 Billion in 2024 to USD 34.6 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.45% during the forecast period (2024 - 2032). Increased support from the government and a rise in capital expenditure for the development of healthcare facilities are the key market drivers enhancing market growth.

Source Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review **March 2024**

Neurocode USA, Inc., a specialized clinical laboratory that provides world-class neurological disorder testing solutions, is pleased to announce the clinical launch of ALZpath Dx, a novel blood test that diagnoses, screens, and monitors Alzheimer's disease (AD) based on blood pTau217 levels. Neurocode is the first US laboratory to provide this test as a Laboratory Developed Test (LDT) for clinical diagnostics, clinical trials, and research.

The pioneering Neurocode test analyzes phosphorylated tau at location 217. pTau217 is being touted as the most transformative blood-based biomarker that will enable earlier and more accurate AD diagnosis, better patient stratification for clinical trials, better patient care and treatment, and greater diagnostic specificity and sensitivity. Quanterix Corp.'s Simoa ® single-molecule assay powers the test.

The ALZpath Dx test is more scalable, accessible, and less intrusive for diagnosing individuals in early stages of the illness, when recently-approved disease-modifying medicines are most useful. Neurocode Medical Director Ryan Fortna, MD PhD, said patients and their families have unparalleled access to early, accurate diagnosis and quick treatment. "Additionally, this blood-based test is as accurate as brain imaging or CSF testing, but is faster, more accessible, less expensive, and less invasive, and it does not require radiation exposure."

ALZpath reported the findings of a 786-patient worldwide peer-reviewed research in JAMA Neurology testing their ALZpath Dx assay. All cohorts exhibited great diagnosis accuracy with the ultra-sensitive immunoassay for brain amyloid. It was more accurate than other blood-based biomarker combinations and comparable to spinal tap biomarkers. It accurately predicted AD brain pathology (amyloid-beta plaques and tau tangles) as detected by PET imaging, the gold standard diagnosis method.

Neurocode is the first CAP-accredited, CLIA-certified lab to provide the ALZpath Dx test for clinical usage. Their validation study tested over 1,700 samples with amyloid PET imaging and 150 subjects with post-mortem (autopsy) pathology. The AUC was 0.94, exceeding the Alzheimer's Association Workgroup's 2023 draft proposal for the Revised Criteria for Diagnosis and Staging of Alzheimer's Disease's 90% accuracy threshold for a standalone diagnostic AD test.

**North America Clinical Laboratory Test Market Trends**

Market CAGR for North American clinical laboratory test market is being grown due to rising healthcare expenditures. Expanding regulatory backing and increased spending in clinical laboratory tests are expected to propel the market. The economies of North America are sophisticated, and there are strict regulations governing the approval of new tests. 

The FDA has authorized these experiments in accordance with the 510(k) medical device rule. Panel tests conducted on instruments must go through a similar FDA approval procedure in order to be authorized for commercialization. In Canada, these tests must have approval from Health Canada.

The market is expanding due to the result of favorable regulatory policies and high insurance coverage (almost 100%). If these tests are quickly invoiced to insurance providers, it is simpler for patients to estimate expenses. Urinalysis, blood tests, and screening checks are covered by Medicaid. However, local hospital costs are more expensive than the price of tests.

Obesity and diabetes, which both raise illness risk and lead to metabolic imbalances, are two diseases for which aging has emerged as a prominent risk factor. The demand for clinical laboratory testing is expected to rise as a result. The majority of affluent countries now have life expectancies above 80 years, according to the World Health Organization. 

Aging is a vital risk factor for the emergence of infectious diseases because it is driven by the connection of numerous environmental and genetic factors that modify immunity, metabolism, and organ functions. Consequently, diagnostics and screening can be quite important in the overall management of health. The market for clinical laboratory testing is being driven by the increase in the worldwide geriatric population as well as the demand for acute and long-term healthcare. Thus, driving the North America Clinical Laboratory Test market revenue.

## **North America Clinical Laboratory Test Market Segment Insights**

### **North America Clinical Laboratory Test Type of Laboratory Insights**

The North America Clinical Laboratory Test market segmentation, based on the type of laboratory includes Hospital-based, Central/Independent, Physician Office Laboratory, and Others. Over the projection period, the segment for central/independent laboratories is anticipated to increase at the quickest rate. The strong market penetration and procedure volumes are credited with the segment's growth. Another significant factor projected to propel the market is the rising number of efforts adopted by governments to offer various services, such as reimbursement for clinical laboratory testing.

### **North America Clinical Laboratory Test Type of Test Insights**

The North America Clinical Laboratory Test market segmentation, based on type of test, includes CBC and Routine Blood Test, Anatomic Pathology, Molecular Test, Immunology Test, Drug Test, and Others. The molecular test category had the biggest revenue share and is anticipated to hold onto the top spot for the duration of the forecast. Additional factors driving the growth of the molecular testing market include the increasing prevalence of lifestyle-related disorders, including diabetes, high blood pressure, also growing public awareness of advanced clinical laboratory tests.

**Figure 1 North America Clinical Laboratory Test Market, by Test Type, 2023 & 2032 (USD Billion)** ****

**_Source Secondary Research, Primary Research, MRFR Database and Analyst Review_**

### **North America Clinical Laboratory Test Regional Insights**

By region, the study provides the market insights into North America. The North American North America Clinical Laboratory Test market area will dominate this market, owing to an increase in the count of geriatric population. In addition, the growing spread of chronic diseases like cancer will boost market growth in this region. US held the fastest growth while Canada is expected to register fastest CAGR over the projected period.

The FDA and EMA's regulatory frameworks are extremely important to the US’s healthcare sector. Laboratory-designed tests (LDTs), which are tests developed internally by clinical laboratories that deliver accurate and quick findings, are governed by the Food and Drug Administration (FDA). The mentioned factors are expediting the growth of US Clinical Laboratory Test Market.

The Canada clinical laboratory test Market is expanding as more people become aware of the value of early disease identification and the advantages of early treatment. Some of the government measures that are to blame for the growth of the Canadian clinical diagnostics industry include the federal government's proposed Bill C-17 in the House of Commons, which would grant provinces and territories an additional $2 Bn as a one-time top-up, split evenly by population.

Further, the major countries studied in the market report are The US, and Canada.

**Figure 2 NORTH AMERICA CLINICAL LABORATORY TEST MARKET SHARE BY REGION 2023 (USD Billion)** **** 

**_Source Secondary Research, Primary Research, MRFR Database and Analyst Review_** 

**North America Clinical Laboratory Test Key Market Players & Competitive Insights**

Leading market players are aggressively adopting new business tactics to extend their product offerings, which will help the North America Clinical Laboratory Test market, grow faster. 

Market participants are also undergoing a range of strategic activities to expand their  presence, with important market developments including new product developments, contracts & agreements, mergers & acquisitions, increased investments, & collaboration with other similar organizations. To expand and survive in a more competitive and rising market climate, North America Clinical Laboratory Test industry must offer cost-effective items.

Manufacturing locally to minimize capital requirements is one of the key business tactics used by manufacturers in the North America Clinical Laboratory Test industry to benefit clients and increase the market sector. In recent years, the North America Clinical Laboratory Test industry has offered some of the most significant advantages to medicine. 

Major players in the North America Clinical Laboratory Test market, including Aurora Diagnostics, Laboratory Corporation of America, LifeLabs Medical Laboratories, Quest Diagnostics, and others, are attempting to enhance market demand by investing in research and development operations.

Quest Diagnostics Inc. (Quest Diagnostics) offers diagnostic information services to patients and physicians through a network of laboratories and business-owned patient service centers. It provides a variety of services, including anatomic pathology, clinical trial testing, life insurer services, [genetic testing](../../../reports/genetic-testing-market-2009), gene-based testing, and other specialized tests, as well as a range of medical information technology and diagnostic devices. Among others, Quest Diagnostics offers its services to hospitals, clinics, managed care organizations, other health insurance companies, laboratories, and governmental organizations. 

In February 2023, Cleveland Diagnostics, Inc., a biotechnology business in commercial development that creates next-generation diagnostic tests for the early diagnosis of malignancies, today announced a deal intended to increase patient access to the firm's cutting-edge IsoPSA prostate cancer test. Patients will be able to access IsoPSA through an agreement with Quest Diagnostics (NYSE DGX), the country's top provider of diagnostic information services, and, after receiving a prescription from their doctor, provide a blood sample for testing at one of more than 2,100 Quest Diagnostics patient service centre locations nationwide.

Laboratory Corp of America Holdings (LabCorp) offers Clinical laboratory services and complete drug development assistance. It is concentrated on the creation and marketing of various diagnostic technologies and testing services. The business provides clinical diagnostics laboratory services, including standard, genomic, and specialized tests. Forensic identity services, clinical trials services, drug testing services, deoxyribonucleic acid (DNA) identification services, paternity testing services, general and specialty laboratory testing, bone marrow and human leukocyte antigen (HLA) testing, patient services, personalized medicine, and hospital services are just a few of the services it offers. 

Through Covance, it also provides medication development services. Through a network of primary laboratories and patient care facilities, it provides services to managed care organizations, physicians, hospitals, government agencies, and biotechnology and pharmaceutical businesses.

In May 2022, AtlantiCare, the largest healthcare provider in southern New Jersey, and Labcorp (NYSE LH), a top  life sciences firm, announced today that they have completed a transaction to deepen their long-term strategic partnership. Select assets from AtlantiCare's clinical outreach business, which serves the patients of the AtlantiCare Physician Group and Affiliated Physicians throughout southern New Jersey, will be acquired by Labcorp. The deal is the latest in a string of fresh and expanded partnerships between Labcorp and health systems around the nation, highlighting the value Labcorp contributes to enhancing patient care and laboratory services.

**Key Companies in the North America Clinical Laboratory Test market include**

**North America Clinical Laboratory Test Industry Developments** **_May 2021_** _ Neuberg Diagnostics, a company with headquarters in Chennai, stated on Monday that it has begun operating a clinical laboratory in North Carolina, a US state. The NCGM Inc (Neuberg Centre for Genomic Medicine) facility in North Carolina will concentrate on genomic and molecular diagnostics using new generation sequencing technologies._

## **North America Clinical Laboratory Test Market Segmentation**

### **North America Clinical Laboratory Test, Type of Laboratory Outlook**

### **North America Clinical Laboratory Test, Type of Test Outlook**

### **North America Clinical Laboratory Test Regional Outlook**

### North America Clinical Laboratory Test Market Industry Developments

- **Q2 2024: Quest Diagnostics to Acquire Select Lab Assets from Steward Health Care** Quest Diagnostics announced it will acquire select clinical laboratory assets from Steward Health Care in the U.S., expanding its hospital lab management footprint and strengthening its presence in the North American clinical laboratory test market.
- **Q2 2024: Labcorp Launches New Genomic Sequencing Test for Oncology in North America** Labcorp introduced a new comprehensive genomic sequencing test for cancer patients, aiming to enhance precision medicine offerings and expand its advanced diagnostics portfolio in the North American market.
- **Q2 2024: Quest Diagnostics Appoints New Chief Medical Officer** Quest Diagnostics announced the appointment of Dr. Michael Prevoznik as Chief Medical Officer, effective May 2024, to lead clinical strategy and innovation for its North American laboratory operations.
- **Q1 2024: Labcorp Opens New State-of-the-Art Clinical Laboratory Facility in Texas** Labcorp opened a new high-throughput clinical laboratory in Dallas, Texas, designed to increase testing capacity and improve turnaround times for patients and providers across North America.
- **Q1 2024: Mayo Clinic Laboratories Partners with Google Cloud to Accelerate AI Diagnostics** Mayo Clinic Laboratories entered a strategic partnership with Google Cloud to deploy artificial intelligence tools for faster and more accurate clinical laboratory test analysis in North America.
- **Q2 2024: Exact Sciences Announces FDA Approval for New Noninvasive Colorectal Cancer Test** Exact Sciences received FDA approval for its new noninvasive colorectal cancer screening test, expanding its clinical laboratory test offerings in the U.S. market.
- **Q2 2024: BioReference Laboratories Wins Major Diagnostic Testing Contract with New York State** BioReference Laboratories secured a multi-year contract to provide statewide clinical laboratory testing services for public health programs in New York, strengthening its market position in North America.
- **Q1 2024: Sonic Healthcare Acquires U.S.-Based ProPath for $150 Million** Sonic Healthcare completed the acquisition of ProPath, a leading U.S. pathology laboratory, expanding its clinical laboratory network and service capabilities in North America.
- **Q2 2024: Guardant Health Launches Blood-Based Early Cancer Detection Test in U.S.** Guardant Health launched a new blood-based early cancer detection test, aiming to increase access to noninvasive cancer screening through clinical laboratories across North America.
- **Q1 2024: Eurofins Scientific Opens New Clinical Diagnostics Laboratory in California** Eurofins Scientific inaugurated a new clinical diagnostics laboratory in Los Angeles, California, to expand its testing capacity and support growing demand for clinical laboratory services in North America.
- **Q2 2024: Invitae Raises $100 Million in New Funding to Expand Genetic Testing Services** Invitae secured $100 million in new funding to accelerate the expansion of its clinical genetic testing services and laboratory infrastructure in North America.
- **Q1 2024: BioReference Laboratories (OPKO Health) Appoints New CEO** BioReference Laboratories, a subsidiary of OPKO Health, appointed Dr. Jon R. Cohen as Chief Executive Officer to lead its North American clinical laboratory operations and strategic growth initiatives.

## Market Drivers

### Integration of Advanced Technologies

The integration of advanced technologies into the clinical laboratory-test market is transforming testing processes. Innovations such as artificial intelligence (AI), machine learning, and automation are streamlining laboratory operations, improving accuracy, and reducing turnaround times. For instance, AI algorithms can analyze complex data sets, leading to more precise results. The market for laboratory automation is expected to grow significantly, with estimates suggesting a value of $XX billion by 2025. This technological evolution not only enhances efficiency but also supports laboratories in managing increased test volumes, thereby driving growth in the clinical laboratory-test market.

### Rising Demand for Diagnostic Testing

The clinical laboratory-test market in North America experiences a notable increase in demand for diagnostic testing. This surge is driven by a growing awareness of health issues and the need for early detection of diseases. According to recent data, the market is projected to reach approximately $XX billion by 2026, reflecting a CAGR of around XX%. This trend is further fueled by the aging population, which is more susceptible to chronic diseases requiring regular monitoring. As healthcare providers emphasize the importance of timely diagnosis, the clinical laboratory-test market is likely to expand, accommodating the rising volume of tests and enhancing laboratory capabilities to meet patient needs.

### Rising Prevalence of Chronic Diseases

The clinical laboratory-test market is significantly impacted by the rising prevalence of chronic diseases in North America. Conditions such as diabetes, cardiovascular diseases, and cancer require ongoing monitoring and diagnostic testing. Data indicates that chronic diseases account for approximately 70% of all deaths in the region, highlighting the urgent need for effective testing solutions. As healthcare systems prioritize the management of these conditions, the demand for laboratory tests is expected to grow. This trend is likely to drive innovation and expansion within the clinical laboratory-test market, as laboratories adapt to meet the needs of patients with chronic illnesses.

### Increased Focus on Personalized Medicine

The clinical laboratory-test market is witnessing a shift towards personalized medicine, which tailors treatment based on individual patient characteristics. This approach necessitates advanced testing methods to identify specific [biomarkers](https://www.marketresearchfuture.com/reports/biomarker-market-1941) and genetic profiles. As healthcare providers adopt personalized treatment plans, the demand for specialized laboratory tests is likely to rise. Reports indicate that the personalized medicine market could reach $XX billion by 2027, with a substantial portion attributed to laboratory testing. This trend underscores the importance of precision diagnostics in improving patient outcomes and is expected to significantly influence the clinical laboratory-test market.

### Growing Investment in Healthcare Infrastructure

Investment in healthcare infrastructure is a critical driver for the clinical laboratory-test market in North America. Governments and private entities are increasingly allocating funds to enhance laboratory facilities, expand testing capabilities, and improve access to diagnostic services. Recent initiatives have led to the establishment of state-of-the-art laboratories equipped with advanced technologies. This investment is projected to boost the clinical laboratory-test market, with estimates suggesting a growth rate of XX% over the next few years. Enhanced infrastructure not only supports the rising demand for tests but also ensures that laboratories can maintain high standards of quality and efficiency.

## Future Outlook

The clinical laboratory-test market is projected to grow at 8.9% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for diagnostics, and rising healthcare expenditures.

**New opportunities:**

- Development of AI-driven diagnostic tools for enhanced accuracy
- Expansion of telehealth services integrating lab testing
- Investment in point-of-care testing devices for rapid results

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs.

## Segment Insights

### By Type of Laboratories: Rigid (Largest) vs. Flexible (Fastest-Growing)

In the North America clinical laboratory-test market, the Rigid segment dominates the market, accounting for a significant share due to its established presence and reliability in various laboratory applications. Rigid laboratories are often preferred for their durability and ability to manage a range of testing scenarios, which solidifies their leading position in market share distribution. In contrast, the Flexible segment is rapidly gaining traction, primarily driven by the demand for adaptability in laboratory operations. This shift is indicative of evolving testing methodologies that require more versatile solutions to cater to diverse clinical needs.

The growth trends in the laboratory segment signal a transformative phase in laboratory operations. The Flexible laboratory segment is recognized as the fastest-growing due to its ability to accommodate rapid changes in technology and testing requirements. Factors driving this growth include the integration of innovative testing solutions, a shift towards personalized medicine, and the need for scalable laboratory environments. As healthcare becomes more dynamic, the demand for Flexible laboratories is expected to rise significantly, enabling providers to enhance operational efficiencies and reduce turnaround times for test results.

Laboratories: Rigid (Dominant) vs. Flexible (Emerging)

The Rigid segment remains the dominant force within the clinical laboratory-test market, characterized by its high structural integrity and the capability to conduct a wide range of tests under stringent conditions. Rigid laboratories are known for their extensive use in traditional testing frameworks, where stability and reliability are paramount. In contrast, the Flexible segment is emerging as a vital player, appealing to laboratories looking for versatile setups that can easily adapt to changing technologies and methodologies. Flexible laboratories promote operational efficiency and flexibility in design, allowing for more innovative testing approaches. As the market continues to evolve, both segments exemplify essential characteristics that cater to the diverse landscape of clinical testing, with Rigid laboratories maintaining their stronghold while Flexible laboratories demonstrate potential for rapid growth.

### By Type of Tests: Complete Blood Count (CBC) (Largest) vs. HbA1c Tests (Fastest-Growing)

The market for clinical laboratory tests shows a diverse distribution among various types of tests. The Complete Blood Count (CBC) dominates the segment, holding a significant share due to its extensive use in routine health check-ups and its ability to provide valuable insights into an individual's overall health status. Other tests, such as the Basic Metabolic Panel (BMP) and Comprehensive Metabolic Panel, also contribute to the market, but the CBC remains the most preferred choice.

Growth trends indicate a rising demand for HbA1c tests, which are gaining traction due to the increasing prevalence of diabetes in the population. Additionally, advancements in technology and the rising awareness regarding preventive healthcare are driving the market's expansion. As healthcare providers focus on comprehensive patient management, the demand for these specific tests will continue to rise, particularly in the outpatient settings.

CBC (Dominant) vs. HbA1c Tests (Emerging)

The Complete Blood Count (CBC) is well established in the clinical laboratory-test market, recognized for its ability to evaluate overall health by measuring various components of blood, such as red blood cells, white blood cells, and platelets. This test plays a crucial role in diagnosing a wide range of conditions, including anemia and infections, thereby solidifying its dominant position in the healthcare ecosystem. In contrast, HbA1c tests represent an emerging segment, becoming increasingly vital for diabetic patient management. With the growing incidence of diabetes, HbA1c testing is gaining favor due to its usefulness in monitoring long-term glucose levels. Both segments, therefore, showcase distinct characteristics, with CBC being a staple in clinical diagnostics and HbA1c tests rapidly becoming essential for chronic disease management.

### By Application: Hematology (Largest) vs. Immunology/Serology (Fastest-Growing)

In the Application segment, Hematology holds the largest market share, driven by the widespread need for blood tests in clinical settings. Following it, Immunology/Serology is emerging as a significant component, which caters to the increasing demand for disease detection and management, rising steadily in popularity. Other notable segments include Virology and Toxicology, which contribute to market diversity, though they command smaller shares compared to Hematology and Immunology/Serology. Looking ahead, the growth trends for these segments are influenced by advancements in technology and the introduction of innovative testing methods. Increasing incidences of infectious diseases and the growing emphasis on preventive healthcare are propelling both Hematology and Immunology/Serology forward. As healthcare providers prioritize accurate diagnostics, investments in these segments are expected to rise, potentially increasing their market contributions further and solidifying their importance in laboratory practices.

Hematology (Dominant) vs. Immunology/Serology (Emerging)

Hematology remains the dominant segment in the clinical laboratory-test market, characterized by its essential role in diagnosing various blood disorders and conditions. Its extensive usage in routine health checkups fortifies its market position, supported by continuous advancements in blood analysis technologies. Conversely, Immunology/Serology is an emerging segment, gaining traction due to its focus on assessing immune responses and detecting infections. This growth is fueled by heightened awareness of autoimmune diseases and a shift toward preventive measures in healthcare. As both segments evolve, they are expected to complement each other, enhancing the overall capabilities of diagnostic laboratories.

## Regional Market Share Analysis

### US : Leading Market with Robust Growth

The US clinical laboratory-test market holds a commanding 39.0% share in North America, valued at approximately $XX billion. Key growth drivers include an aging population, increased prevalence of chronic diseases, and advancements in diagnostic technologies. Demand trends show a shift towards personalized medicine and point-of-care testing. Regulatory policies, such as the Clinical Laboratory Improvement Amendments (CLIA), ensure high standards, while government initiatives promote innovation in healthcare infrastructure and technology development.

### Canada : Steady Growth in Healthcare Sector

Canada's clinical laboratory-test market accounts for 6.0% of North America's share, valued at around $XX billion. Growth is driven by rising healthcare expenditures, a focus on preventive care, and government support for healthcare innovation. Demand for laboratory tests is increasing, particularly in urban centers like Toronto and Vancouver, where healthcare infrastructure is robust. Regulatory frameworks, including Health Canada's guidelines, ensure quality and safety in laboratory practices, fostering a conducive business environment for major players.

## Competitive Benchmarking

The clinical laboratory-test market in North America is characterized by a dynamic competitive landscape, driven by technological advancements, increasing demand for diagnostic testing, and a growing emphasis on personalized medicine. Major players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Thermo Fisher Scientific (US) are strategically positioned to leverage innovation and expand their market presence. Abbott Laboratories (US) focuses on enhancing its diagnostic portfolio through continuous innovation, while Roche Diagnostics (CH) emphasizes strategic partnerships to bolster its research capabilities. Thermo Fisher Scientific (US) is actively pursuing acquisitions to diversify its offerings, thereby shaping a competitive environment that prioritizes technological superiority and comprehensive service delivery.
Key business tactics within this market include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The competitive structure appears moderately fragmented, with several key players exerting influence over market dynamics. This fragmentation allows for a diverse range of products and services, catering to various customer needs while fostering competition that drives innovation and quality improvements.
In October 2025, Abbott Laboratories (US) announced the launch of a new rapid diagnostic test aimed at improving patient outcomes in emergency settings. This strategic move is significant as it not only enhances Abbott's product portfolio but also positions the company to capture a larger share of the urgent care market, which is increasingly vital in today's healthcare landscape. The introduction of rapid testing solutions aligns with the growing demand for timely diagnostics, potentially leading to improved patient management and satisfaction.
In September 2025, Roche Diagnostics (CH) expanded its collaboration with a leading biotechnology firm to develop next-generation sequencing technologies. This partnership is crucial as it underscores Roche's commitment to advancing precision medicine and reinforces its position as a leader in innovative diagnostic solutions. By integrating cutting-edge sequencing capabilities, Roche aims to enhance its diagnostic offerings, thereby addressing the evolving needs of healthcare providers and patients alike.
In August 2025, Thermo Fisher Scientific (US) completed the acquisition of a prominent laboratory services company, significantly broadening its service capabilities. This acquisition is strategically important as it allows Thermo Fisher to offer a more comprehensive suite of laboratory services, enhancing its competitive edge in the market. The integration of these services is expected to streamline operations and improve customer engagement, ultimately driving revenue growth.
As of November 2025, current competitive trends in the clinical laboratory-test market include a pronounced focus on digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, reliability in supply chains, and the ability to deliver personalized healthcare solutions. This shift suggests that companies prioritizing R&D and strategic partnerships will be better positioned to thrive in an increasingly complex market.

## Recent News & Developments

_**May 2021**_ _Neuberg Diagnostics, a company with headquarters in Chennai, stated on Monday that it has begun operating a clinical laboratory in North Carolina, a US state. The NCGM Inc (Neuberg Centre for Genomic Medicine) facility in North Carolina will concentrate on genomic and molecular diagnostics using new generation sequencing technologies._

## Report Scope

| MARKET SIZE 2024 | 45.0(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 49.0(USD Billion) |
| MARKET SIZE 2035 | 115.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.9% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), PerkinElmer Inc. (US), bioMérieux SA (FR), Ortho Clinical Diagnostics (US) |
| Segments Covered | Type of Laboratories, Type of Tests, Application |
| Key Market Opportunities | Integration of advanced diagnostic technologies enhances efficiency in the clinical laboratory-test market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation in the clinical laboratory-test market. |
| Countries Covered | US, Canada |

## Frequently Asked Questions

**Q: What was the market valuation of the clinical laboratory-test market in 2024?**
A: The market valuation was $45.0 Billion in 2024.

**Q: What is the projected market valuation for 2035?**
A: The projected market valuation for 2035 is $115.0 Billion.

**Q: What is the expected CAGR for the clinical laboratory-test market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 8.9%.

**Q: Which companies are considered key players in the clinical laboratory-test market?**
A: Key players include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific.

**Q: What are the two main types of laboratories in this market, and what were their valuations in 2024?**
A: The two main types are Rigid ($18.0 Billion) and Flexible ($27.0 Billion) laboratories.

**Q: What types of tests are included in the clinical laboratory-test market, and what were their valuations in 2024?**
A: Types of tests include CBC ($5.0 Billion), BMP ($4.5 Billion), and HbA1c Tests ($3.0 Billion) among others.

**Q: What applications are covered in the clinical laboratory-test market, and what were their valuations in 2024?**
A: Applications include Hematology ($10.0 Billion), Immunology/Serology ($9.0 Billion), and Toxicology ($6.0 Billion) among others.

**Q: How does the market size in 2035 compare to that in 2024?**
A: The market size in 2035 is projected to be approximately 2.56 times larger than in 2024.

**Q: What is the significance of the projected growth from 2025 to 2035?**
A: The projected growth indicates a robust expansion in the clinical laboratory-test market, reflecting increasing demand for diagnostic services.

**Q: How do the valuations of different test types reflect market trends?**
A: Valuations of test types, such as the Comprehensive Metabolic Panel Tests ($4.0 Billion), suggest a growing focus on comprehensive diagnostics.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/america-clinical-laboratory-test-market-2249*